A Parkinson's Pill That Skips Dopamine Cut Off Time by 37 Minutes

Cerevance, a private company in Boston, announced on October 7, 2026 that its once daily pill solengepras met the primary endpoint of ARISE, a phase 3 trial in Parkinson's disease. The results were presented the same day at the International Congress of Parkinson's Disease and Movement Disorders in Seoul. One point comes first: every number in this article comes from the company's press release and its congress presentation. The trial has not been published in a peer reviewed journal, so the full methods, all prespecified analyses and the detailed safety tables are not yet available to check.

What is different about the drug

Most Parkinson's medicines work on dopamine, either by replacing it, as levodopa does, or by mimicking or prolonging it. Over years, many patients develop motor fluctuations: periods called OFF when symptoms return between doses. Add on dopamine drugs can shorten OFF time but often bring dyskinesia, involuntary movements, and daytime sleepiness.

Solengepras takes another route. It blocks a receptor called GPR6, found in a pathway of the basal ganglia known as the indirect pathway, and has no direct action on dopamine receptors. That is why Cerevance calls it potentially first in class.

What ARISE measured

The trial randomized 341 people with Parkinson's disease, all with at least three hours of daily OFF time on average despite their usual medicines, which they kept taking. They were assigned in equal groups to solengepras 75 mg (114 people), 150 mg (113) or placebo (114) for 12 weeks. At baseline, participants averaged 5.65 hours of OFF time a day. Of the 341, 311 completed the trial.

The primary endpoint compared the 150 mg dose with placebo. Average daily OFF time fell by 1.56 hours on solengepras and 0.95 hours on placebo, a difference of 0.61 hours, about 37 minutes (p=0.0350). The gap appeared at week 2 and held at each visit. The key secondary endpoint, ON time without troublesome dyskinesia, rose by 0.60 hours more than placebo (p=0.0468). Daily living scores on Part II of the movement disorder rating scale improved by 1.91 points more than placebo (p=0.0008). Daytime sleepiness and a quality of life questionnaire also improved, but those p values are nominal: they were not part of the formal testing sequence.

The release reports results for the 150 mg dose in detail and gives little efficacy data for 75 mg.

The placebo group matters as much as the drug group here. People on placebo also cut their daily OFF time by almost an hour, 0.95 hours, which is typical in Parkinson's trials where patients record their own symptoms in home diaries. The drug's effect is the difference on top of that, which is why 1.56 hours from baseline shrinks to 0.61 hours once placebo is subtracted. A headline that quotes the larger number overstates the drug.

Safety, as reported

The company describes the drug as generally well tolerated. Discontinuation for adverse events was 3.5% in all three arms, including placebo. No serious adverse events were reported on 150 mg, against 1.8% on 75 mg and 0.9% on placebo. Dyskinesia, the side effect the new mechanism is meant to avoid, was reported in 4.4% on 150 mg against 1.8% on placebo: low, but not zero, and higher than placebo. The most common adverse events on 150 mg were headache (8.0% against 3.5%), urinary tract infection (8.0% against 6.1%), insomnia (6.2% against 0.9%) and nausea (6.2% against 1.8%).

What comes next

Cerevance says it will meet the FDA to discuss a possible new drug application. No application has been filed. The company's ARISE listing on ClinicalTrials.gov is NCT06553027. Before any regulator decides, the field will want the full paper: how missing data were handled for the 30 people who did not finish, what happened at 75 mg, and whether patient diaries of OFF time, which are self reported, line up with the clinician rated scores. Those are the standard checks in our guide to reading a health study. Nothing here is treatment advice; patients should discuss any change with their neurologist.

I read this as a real but modest result with an interesting mechanism. About 37 minutes less OFF time a day is in the range regulators have accepted for add on Parkinson's drugs, and doing it without acting on dopamine is new. The open question is whether the full paper keeps the picture as clean as the press release, especially at the lower dose and on dyskinesia, the one side effect this drug was designed to spare.